Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma by unknown
LETTER TO THE EDITOR Open Access
Different clinical characteristics and
treatment strategies for patients with
localized sinonasal diffuse large B cell
lymphoma and extranodal NK/T cell
lymphoma
Yu Huang, Bo Jia, Shiyu Jiang, Shengyu Zhou, Jianliang Yang, Peng Liu, Lin Gui, Xiaohui He, Yan Qin, Yan Sun
and Yuankai Shi*
Abstract
The difference in clinical features and treatment outcomes between localized sinonasal diffuse large B cell lymphoma
(SN-DLBCL) and sinonasal extranodal NK/T cell lymphoma (SN-ENKTL) is unclear. Therefore, we analyzed a total of 47
patients with localized SN-DLBCL and 211 patients with localized SN-ENKTL. The age distribution for these two subtypes
is very distinct and the B symptoms were more common in SN-ENKTL. However, both SN-DLBCL and SN-ENKTL patients
could achieve high overall response rate (ORR) and favorable prognoses. The 3-year overall survival (OS) rates for patients
with SN-DLBCL and SN-ENKTL were 79.7 and 83.6% (p = 0.707), and the 3-year progression-free survival (PFS) rates were
61.4 and 70.1% (p = 0.294), respectively. For SN-DLBCL patients, chemotherapy followed by involved-field radiotherapy
(IFRT) resulted in higher OS (83.7 vs 62.5%) and PFS (63.9 vs 50.0%) compared with chemotherapy alone, but
the difference was not significant. No significant difference was found in the OS or PFS between radiotherapy
alone and radiotherapy combined with chemotherapy for all patients with SN-ENKTL. But in extensive stage I
and stage II SN-ENKTL patients, radiotherapy combined with chemotherapy could significantly improve the PFS
(73.8 vs 50.0%) compared with radiotherapy alone. These results indicate that remarkable clinical disparities
exist between localized SN-DLBCL and SN-ENKTL. However, different treatment strategies for them can result
in similarly favorable prognoses.
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Dear Editor
Remarkable differences exist in the distribution of
lymphoma subtypes between China and western popula-
tions. The incidence of extranodal NK/T cell lymphoma
(ENKTL) is much higher in China [1, 2]. Diffuse large B
cell lymphoma (DLBCL) and ENKTL are most common
subtypes of sinonasal lymphomas. What is more, both
sinonasal DLBCL (SN-DLBCL) and sinonasal ENKTL
(SN-ENKTL) are typically diagnosed in the localized
stage which represents 70–90% of cases [3, 4]. Since the
difference between localized SN-DLBCL and SN-ENKTL
has seldom been demonstrated before and is not clear, this
study provides a comprehensive evaluation that focuses
on clinical features and prognoses of localized SN-DLBCL
and SN-ENKTL in Chinese patients.
A total of 47 consecutive patients with localized SN-
DLBCL and 211 patients with localized SN-ENKTL from
2000 to 2014 were compared at the Cancer Hospital of
Chinese Academy of Medical Sciences and Peking Union
Medical College, Beijing, China. The methods used in
this study are detailed in Additional file 1. This study
showed that the incidence of SN-ENKTL was much
higher than that of SN-DLBCL in China, which was
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Table 1 Clinical characteristics of patients with localized SN-DLBCL and SN-ENKTL
Characteristic All patients
(n = 258), n (%)
SN-DLBCL
(n = 47), n (%)
SN-ENKTL




Male 174 (67.4) 25 (53.2) 149 (70.6) 0.021
Female 84 (32.6) 22 (46.8) 62 (29.4)
Age (year)
Median (range) 43 (10–85) 63 (11–82) 40 (10–85) <0.001
≤60 225 (87.2) 25 (53.2) 200 (94.8)
>60 33 (12.8) 22 (46.8) 11 (5.2)
Modified Ann Arbor stage
Limited I 73 (28.3) 3 (6.4) 70 (33.2) 0.001
Extensive I 126 (48.8) 32 (68.1) 94 (44.5)
II 59 (22.9) 12 (25.5) 47 (22.3)
Nodal involvement
Present 49 (19.0) 10 (21.3) 39 (18.5) 0.659
Absent 209 (81.0) 37 (78.7) 172 (81.5)
B symptoms
Present 104 (40.3) 5 (10.6) 99 (46.9) <0.001
Absent 154 (59.7) 42 (89.4) 112 (53.1)
LDH level
Normal 192 (74.4) 37 (78.7) 155 (73.5) 0.514
Elevated 64 (24.8) 10 (21.3) 54 (25.6)
Unknown 2 (0.8) 0 (0.0) 2 (0.9)
ECOG performance status
0 141 (54.7) 25 (53.2) 116 (55.0) 0.018
1 94 (36.4) 13 (27.7) 81 (38.4)
≥2 23 (8.9) 9 (19.1) 14 (6.6)
mIPI
0 126 (48.8) 13 (27.7) 113 (53.6) 0.001
1 92 (35.7) 20 (42.5) 72 (34.1)
2–4 38 (14.7) 14 (29.8) 24 (11.4)
Unknown 2 (0.8) 0 (0.0) 2 (0.9)
Treatment strategy
CMT 147 (57.0) 37 (78.7) 110 (52.1) <0.001
Chemotherapy alone 17 (6.6) 10 (21.3) 7 (3.3)
Radiotherapy alone 94 (36.4) 0 (0.0) 94 (44.6)
Response to treatment
CR/CRu 205 (79.5) 36 (76.6) 169 (80.1) 0.686
PR 23 (8.9) 6 (12.7) 17 (8.1)
SD 1 (0.4) 0 (0.0) 1 (0.5)
PD 15 (5.8) 2 (4.3) 13 (6.2)
Not evaluable 14 (5.4) 3 (6.4) 11 (5.1)
SN-DLBCL sinonasal diffuse large B cell lymphoma, SN-ENKTL sinonasal extranodal NK/T cell lymphoma, LDH lactate dehydrogenase, ECOG Eastern Cooperative
Oncology Group, mIPI modified International Prognostic Index, CMT combined modality therapy, CR complete response, CRu unconfirmed complete response, PR
partial response, SD stable disease, PD progressive disease
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opposite to the situation in the USA [4]. The ratio of
males to females was 1.14:1 in SN-DLBCL and 2.40:1 in
SN-ENKTL. Patients with SN-DLBCL had a higher
median age (63 years old) than those with SN-ENKTL
(40 years old). The B symptoms were more common in
SN-ENKTL. The comparison of the main clinical
characteristics between these two groups is presented
in Table 1.
The overall response rates (ORR) after completion of
therapy were equally high for patients with SN-DLBCL and
SN-ENKTL (89.3 vs 88.2%). For patients with SN-DLBCL,
the ORR was 94.6% after chemotherapy followed by
involved-field radiotherapy (IFRT) and 70% after chemo-
therapy alone. For patients with SN-ENKTL receiving
radiotherapy combined with chemotherapy (combined mo-
dality therapy, CMT) and radiotherapy alone, the ORR
were 91.8 and 87.2%. In CMT SN-ENKTL patients, the
ORR and complete response (CR) rates were both 100% for
chemotherapy containing pegaspargase or gemcitabine
combined with radiotherapy group. In contrast, the ORR
and CR rates were 87.1 and 79.0% for conventional chemo-
therapy regimens (cyclophosphamide, doxorubicin, vincris-
tine, and prednisone, CHOP/CHOP-like) combined with
radiotherapy group. In addition, the ORR was only 42.9%
for patients with SN-ENKTL receiving chemotherapy alone
which mainly consists of CHOP or CHOP-like regimens.
The treatment outcomes were similar between SN-
DLBCL and SN-ENKTL. The 3-year overall survival
(OS) and progression-free survival (PFS) rates were 79.7
and 61.4% for SN-DLBCL and 83.6 (p = 0.707) and
70.1% (p = 0.294) for SN-ENKTL, respectively (Fig. 1).
Unfavorable Eastern Cooperative Oncology Group
(ECOG) performance status (PS) and failure to achieve
CR were significantly associated with worse OS and PFS
for SN-DLBCL patients (Additional file 2). For patients
with SN-ENKTL, factors related to worse OS and PFS
included unfavorable modified Ann Arbor stage and fail-
ure to achieve CR (Additional file 2). In addition, higher
modified International Prognostic Index (mIPI) [5] was
significantly associated with worse OS but not signifi-
cantly associated with worse PFS (Additional file 2).
Although a short course of rituximab-CHOP (R-
CHOP) chemotherapy followed by IFRT is the recom-
mended treatment option for localized DLBCL, the
treatment strategy for SN-DLBCL has seldom been
explored because of limited cases. Lee et al. [6] found
no significant differences in response rate and OS be-
tween patients with SN-DLBCL treated with R-CHOP
chemotherapy alone and those treated with R-CHOP
chemotherapy followed by IFRT. In our study, some
patients were treated with CHOP or CHOP-like regi-
mens without rituximab; the 3-year OS rates were
83.7% for patients receiving chemotherapy followed by
IFRT and 62.5% for those receiving chemotherapy
alone, but the difference was not significant (p = 0.113,
Additional file 3).
Because of their different chemosensitivities, the
treatment options for patients with ENKTL differ from
those for patients with DLBCL. Currently, the optimal
combination treatment modalities for localized SN-
ENKTL have not been defined. Treatment options
include radiotherapy alone, sequential chemotherapy
and radiotherapy, or concurrent chemoradiotherapy
[7, 8]. In this study, no significant difference was
found in the OS or PFS between radiotherapy alone
and CMT for all patients with localized SN-ENKTL
(Additional file 4). But in extensive stage I and stage II
SN-ENKTL group, CMT could significantly improve
the PFS (73.8 vs 50.0%, p = 0.003) compared with
radiotherapy alone, and CMT achieved higher 3-year
OS rate though the difference was not significant
(Additional file 4). In all SN-ENKTL patients receiving
the CMT, chemotherapy containing pegaspargase or
gemcitabine could achieve higher 3-year OS and PFS
rates than conventional CHOP/CHOP-like chemotherapy
regimens, but the difference was not significant.
a b
Fig. 1 a Overall survival and b progression-free survival for patients with localized sinonasal diffuse large B cell lymphoma (SN-DLBCL, n = 47) and
sinonasal extranodal NK/T cell lymphoma (SN-ENKTL, n = 211)
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In conclusion, the data from our study revealed that
localized SN-DLBCL and SN-ENKTL had different clinical
characteristics, but both of these two subtypes could
achieve favorable prognoses. These results highlight that
the heterogeneity of sinonasal lymphomas and therapeutic
approaches should be selected according to the specific
subtype and the stage at diagnosis.
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